Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome.
Patients with Smith-Lemli-Opitz syndrome (SLOS) are born with multiple congenital abnormalities. Postnatal cholesterol supplementation is provided; however, it cannot correct developmental malformations due to in utero cholesterol deficit. Increased transport of cholesterol from maternal to fetal circulation might attenuate congenital malformations. The cholesterol transporters Abca1, Abcg1, and Sr-b1 are present in placenta; however, their potential role in placental transport remains undetermined. In mice, expression analyses showed that Abca1 and Abcg1 transcripts increased 2-3-fold between embryonic days 13.5 and 18.5 in placental tissue; whereas, Sr-b1 expression decreased. To examine the functional role of Abca1, Abcg1 and Sr-b1 we measured the maternal-fetal transfer of (14)C-cholesterol in corresponding mutant embryos. Disruption of either Abca1 or Sr-b1 decreased cholesterol transfer by approximately 30%. In contrast, disruption of the Abcg1 had no effect. Treatment of pregnant C57Bl/6 female mice with TO901317, an LXR-agonist, increased both Abca1 expression and maternal-fetal cholesterol transfer to the fetus. In an SLOS mouse model (Dhcr7(-/-)), which is incapable of de novo synthesis of cholesterol, in utero treatment with TO901317 resulted in increased cholesterol content in Dhcr7(-/-) embryos. Our data support the hypothesis that Abca1, and possibly Sr-b1, contributes to transport maternal cholesterol to the developing fetus. Furthermore, we show, as a proof of principle, that modulating maternal-fetal cholesterol transport has potential for in utero therapy of SLOS.
Lindegaard
Marie L
ML
Section on Molecular Dysmorphology, Eunice Kennedy Schriver National Institute of Child Health and Human Development, National Heart, Lung and Blood Institute, NIH, DHHS, Bethesda, MD, USA. marie.s.lindegaard@dadlnet.dk
Wassif
Christopher A
CA
Vaisman
Boris
B
Amar
Marcelo
M
Wasmuth
Elizabeth V
EV
Shamburek
Robert
R
Nielsen
Lars B
LB
Remaley
Alan T
AT
Porter
Forbes D
FD
D064286:ATP Binding Cassette Transporter 1; D000070998:ATP Binding Cassette Transporter, Subfamily G, Member 1; D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D001692:Biological Transport; D002784:Cholesterol / Q000378:metabolism*; D005260:Female; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000627:therapeutic use; D008074:Lipoproteins / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D010920:Placenta / Q000378:metabolism*; D021041:Placental Circulation; D011247:Pregnancy; D019082:Smith-Lemli-Opitz Syndrome / Q000196:embryology / Q000378:metabolism* / Q000628:therapy*; D013449:Sulfonamides / Q000627:therapeutic use; D014599:Uterus / Q000378:metabolism*; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
D064286:ATP Binding Cassette Transporter 1; D000070998:ATP Binding Cassette Transporter, Subfamily G, Member 1; D018528:ATP-Binding Cassette Transporters; D002784:Cholesterol; D006845:Hydrocarbons, Fluorinated; D008074:Lipoproteins; D013449:Sulfonamides; C577836:ABCA1 protein, human; C487540:ABCG1 protein, mouse; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
J Lipid Res. 1995 Aug;36(8):1774-86
7595098
J Clin Invest. 2001 Dec;108(11):1717-22
11733567
Vascul Pharmacol. 2002 Apr;38(4):249-56
12449021
Hum Mol Genet. 2001 Mar 15;10(6):555-64
11230174
J Lipid Res. 2006 Nov;47(11):2433-43
16902247
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12610-5
9356497
Science. 2001 Nov 30;294(5548):1866-70
11729302
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4245-50
10760292
Mol Hum Reprod. 2007 Jun;13(6):373-9
17449538
Placenta. 2007 Jul;28(7):604-10
17141866
Placenta. 2007 Jul;28(7):701-8
17113147
J Biol Chem. 2000 Sep 8;275(36):28240-5
10858438
Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2308-15
16917103
Teratology. 1990 Apr;41(4):361-81
2187257
J Clin Invest. 1972 Oct;51(10):2584-92
4626846
Mol Genet Metab. 2008 Jun;94(2):240-7
18346920
Placenta. 1991 Nov-Dec;12(6):615-24
1666673
Cell Metab. 2005 Feb;1(2):121-31
16054053
J Lipid Res. 1997 Jul;38(7):1289-98
9254056
J Clin Invest. 2006 Mar;116(3):607-14
16511593
Int J Biochem Cell Biol. 2006;38(8):1314-29
16530456
J Biol Chem. 2002 Sep 13;277(37):34182-90
12097330
Fetal Diagn Ther. 1999 May-Jun;14(3):133-7
10364662
J Lipid Res. 1998 Mar;39(3):495-508
9548583
Am J Clin Nutr. 2005 Dec;82(6):1155-61
16332646
J Lipid Res. 1999 Mar;40(3):575-80
10064746
Nat Genet. 2000 Feb;24(2):192-6
10655069
Int J Cardiol. 2007 Jan 31;115(1):29-35
16766063
J Lipid Res. 1967 Nov;8(6):558-64
6057485
Placenta. 2005 Nov;26(10):721-8
16226121
J Intern Med. 2008 Mar;263(3):256-73
18271871
Science. 1996 Jan 26;271(5248):518-20
8560269
J Lipid Res. 2004 Nov;45(11):2052-62
15292368
Am J Obstet Gynecol. 1977 Aug 1;128(7):735-9
879241
Anat Rec A Discov Mol Cell Evol Biol. 2005 Mar;283(1):175-81
15674823
Mol Genet Metab. 2005 Jun;85(2):96-107
15896653
J Clin Invest. 1993 Mar;91(3):923-38
8450070
J Biol Chem. 2000 May 12;275(19):14700-7
10799558
Placenta. 2002 Jan;23(1):3-19
11869088
Clin Chim Acta. 1995 Apr 30;236(1):45-58
7664465
Curr Opin Lipidol. 2000 Jun;11(3):253-60
10882340
J Lipid Res. 2007 Feb;48(2):373-84
17088262
J Clin Invest. 2007 Dec;117(12):3900-8
17992262
Am J Obstet Gynecol. 1968 Jun 15;101(4):534-8
5655399
Clin Chem. 2003 Feb;49(2):230-8
12560344
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9774-9
15210959
Placenta. 2003 Feb-Mar;24(2-3):131-43
12566239
J Lipid Res. 2003 Oct;44(10):1909-18
12897187
J Biol Chem. 2004 Mar 26;279(13):12448-55
14718538
Am J Pathol. 2000 Sep;157(3):1017-29
10980140
Eur J Hum Genet. 2008 May;16(5):535-41
18285838
J Med Genet. 2004 Aug;41(8):577-84
15286151